Damora Therapeutics (DMRA) Non Operating Income (2019 - 2026)
Damora Therapeutics (DMRA) posted Non Operating Income of $3.1 million for Q1 2026, up 205.78% on a QoQ basis from $1.0 million in Q4 2025, and up 4414.71% year-over-year from $68000.0 in Q1 2025.
Damora Therapeutics (DMRA) Non Operating Income (2019 - 2026) Analysis & Trends
Damora Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- Quarterly Non Operating Income rose 4414.71% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 513.36% YoY) and the FY2025 annual result came in at $1.1 million, up 25.64% from the prior year.
- Non Operating Income was $3.1 million for Q1 2026 at Damora Therapeutics, up from $1.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.1 million in Q1 2026 and bottomed at -$544000.0 in Q4 2022.
- A 5-year average of $362000.0 and a median of $234000.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 1022.03% — and 2023, when it jumped 49700.0%.
- Damora Therapeutics' Non Operating Income stood at -$544000.0 in 2022, then surged by 136.03% to $196000.0 in 2023, then soared by 80.1% to $353000.0 in 2024, then jumped by 184.42% to $1.0 million in 2025, then surged by 205.78% to $3.1 million in 2026.
- Business Quant data shows DMRA's Non Operating Income at $3.1 million in Q1 2026, $1.0 million in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 353,000.00 |
| Sep 30, 2024 | -36,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 264,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 415,000.00 |
| Mar 31, 2023 | 498,000.00 |
| Dec 31, 2022 | -544,000.00 |
| Sep 30, 2022 | -108,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 59,000.00 |
| Sep 30, 2021 | 243,000.00 |
| Jun 30, 2021 | -34,000.00 |